Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
A lack of profits can lead to trouble, but StockStory helps you identify the businesses that stand a chance of making it through. Keeping that in mind, here are three unprofitable companiesthat don’t make the cut and some better opportunities instead.
Albany (AIN)
Trailing 12-Month GAAP Operating Margin: -2.2%
Founded in 1895, Albany (NYSE:AIN) is a global textiles and materials processing company, specializing in machine clothing for paper mills and engineered composite structures for aerospace and other industries.
Why Do We Avoid AIN?
- 1.5% annual revenue growth over the last two years was slower than its industrials peers
- 10.7 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position
- Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions
Albany is trading at $57.90 per share, or 23.7x forward P/E. Check out our free in-depth research report to learn more about why AIN doesn’t pass our bar.
Strategy (MSTR)
Trailing 12-Month GAAP Operating Margin: -1,141%
Once a traditional business intelligence software provider, Strategy (NASDAQ:MSTR) develops AI-powered enterprise analytics software while also functioning as a major corporate holder of Bitcoin cryptocurrency.
Why Is MSTR Risky?
- MicroStrategy’s core analytics software has been eclipsed by its all-in Bitcoin strategy, leaving product innovation and enterprise deals starved for attention
- The company’s debt-financed Bitcoin buying ties shareholder fortunes to crypto swings and interest rates, amplifying downside risk and uncertainty
- On the bright side, its vast Bitcoin treasury gives Executive Chairman Michael Saylor a unique springboard to capture crypto upside and court investors seeking leveraged exposure to digital assets
At $134.85 per share, Strategy trades at 76.4x forward price-to-sales. Read our free research report to see why you should think twice about including MSTR in your portfolio.
Supernus Pharmaceuticals (SUPN)
Trailing 12-Month GAAP Operating Margin: -8.7%
With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals (NASDAQ:SUPN) develops and markets treatments for central nervous system disorders including epilepsy, ADHD, Parkinson's disease, and migraine.
Why Are We Cautious About SUPN?
- Annual revenue growth of 5.6% over the last five years was below our standards for the healthcare sector
- Revenue base of $717.2 million puts it at a disadvantage compared to larger competitors exhibiting economies of scale
- Free cash flow margin dropped by 14.4 percentage points over the last five years, implying the company became more capital intensive as competition picked up
Supernus Pharmaceuticals’s stock price of $49.90 implies a valuation ratio of 21.5x forward P/E. Dive into our free research report to see why there are better opportunities than SUPN.
Stocks We Like More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.